Bioventus Names Greg Anglum Senior Vice President And Chief Financial Officer, Tony D’Adamio Senior Vice President And General Counsel
Published: Aug 07, 2017
DURHAM, N.C.--(BUSINESS WIRE)--Bioventus®, a leader in orthobiologic solutions, today announced two changes to its executive leadership team. Greg Anglum has been promoted to Senior Vice President and Chief Financial Officer. Anglum, who joined Bioventus in 2016 as its Chief Accounting Officer, brings more than 20 years of experience driving financial and growth strategies for both private and public companies in various industries. He will also be responsible for the business intelligence and IT teams at Bioventus.
In addition, Bioventus is pleased to announce Anthony (Tony) D’Adamio has joined the company as its Senior Vice President and General Counsel. D’Adamio has nearly 30 years of senior legal executive experience with diagnostic, health care data and clinical service companies. He will be responsible for all general and corporate legal matters as well as the ethics and compliance functions at Bioventus. Both Anglum and D’Adamio will also join the company’s executive leadership team and report to its CEO, Tony Bihl.
“Greg has done an exceptional job serving as Interim CFO for the past three months, seamlessly integrating into our executive team in this important role. He has provided the financial reporting, guidance, analysis, and leadership that gives us great confidence in his ability to perform and grow moving forward,” said Bihl. “One of Tony’s strengths is his ability to provide exceptional legal advice while always seeking to achieve the best overall business solution. His global experience in complex regulated healthcare industries, along with his engaging and collaborative approach make him a great addition to our leadership team.”
Prior to joining Bioventus, Anglum held CFO positions at Overture, a Raleigh-based technology company and StrikeIron, a Software-as-a-Service (SaaS) company. He also spent several years in public accounting roles with Arthur Andersen and Grant Thornton. Anglum earned a Bachelor of Arts degree in economics from Vanderbilt University and an MBA from the Owen Graduate School of Management at Vanderbilt.
D’Adamio most recently served as General Counsel & Secretary of Siemens Medical Solutions and earlier was Deputy General Counsel & Secretary of Siemens Healthcare Diagnostics. He also spent five years as Senior Counsel within the Diagnostics Division of Bayer Healthcare, prior to the acquisition of this business by Siemens. D’Adamio began his legal career at the law firm of Bond, Schoeneck & King before taking corporate legal positions with companies including Group Health Incorporated, Quest Diagnostics and Covance. He received his Juris Doctor cum laude from Howard University School of Law and a Bachelor of Arts from the State University of New York at Binghamton.
Bioventus is an orthobiologics company that delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The company has two product portfolios for orthobiologics, Bioventus Active Healing Therapies and Bioventus Surgical that make it a global leader in active orthopaedic healing. Its EXOGEN® Ultrasound Bone Healing System uses safe, effective low intensity pulsed ultrasound (LIPUS) to stimulate the body’s natural healing process. EXOGEN has been used to treat more than 1 million patients worldwide and numerous regulatory agencies including the FDA, Health Canada, BSi, TGA, Medsafe, UAE Ministry of Health and SFDA have granted their approval of the product. Today it is the leading bone healing system in the market with complaints for lack of efficacy averaging less than 1%.
Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide. For more information, visit www.BioventusGlobal.com and follow the company on Twitter @Bioventusglobal.
Bioventus, the Bioventus logo and EXOGEN are registered trademarks of Bioventus LLC.
Thomas Hill, 919-474-6715